Hyperion raises $40 million in venture funds

South San Francisco’s Hyperion Therapeutics, a biopharmaceutical firm specializing in gastrointestinal and hepatology therapies, has raised $40 million in a second round of venture funding.

Sofinnova Ventures was the lead investor, with equal commitments from Highland Capital Partners and NEA, all of them based in Menlo Park.

WRF Capital of Seattle, Wash. also invested.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

‘Shared Spaces’ program will let restaurants, retail expand into outdoor spaces

City to grant permits for use of sidewalks, parking for business operations

Texts show Mayor Breed ordering police chief to ‘clear’ out homeless

Newly released text messages are offering the public a behind-the-scenes glimpse of… Continue reading

Hair salons, barbershops can reopen now, in Stage 3 of Newsom’s plan

By Taryn Luna Los Angeles Times Gov. Gavin Newsom issued welcome news… Continue reading

State issues guidelines allowing places of worship to resume services

Local black ministers, civil rights leaders call for churches to remain closed

Advocates want more public notice before SF euthanizes an animal

Animal control officials say web posting proposal would eat up resources, change few outcomes

Most Read